|
|
Case studies
EPS
| |
| Project name |
Academic |
Description |
| |
| Transitive Corporation |
Prof. Alasdair Rawsthorne |
Alasdair Rawsthorne from the School of Computer Science started the intial research which went on to form the basis of Transitive Corporation in 1995 and the company spun out of the University in 2000. Transitive's technology enables software applications to run on any computer platform without requiring any changes to the software. Transitive raised over $30M in various funding rounds and were bought by IBM in November 2008. |
| |
| Acoustek |
Prof Barry Lennox |
Professor Barry Lennox from the School of Electronic and Electrical Engineering has developed Acoustek -a technology which quickly and accurately detects blockages and leaks in gas pipelines. Acoustek attracted over £500,000 from sources including BP for further development and was recently licensed to Pipeline Engineering Ltd for commercialisation. Please see the following link for updated information:
http://www.pipelineengineering.com/acoustek.php
|
| |
| |
FLS
| |
| Project name |
Academic |
Description |
| |
| Monoclonal Antibody - Vitamin D |
Professor Anne White in collaboration with Professor Barbara Mawer |
Professor Anne White from the Faculty of Life Sciences developed a monoclonal antibody whilst working in collaboration with Professor Barbara Mawer, a colleague in the field of endocrinology. The antibody was licensed on an exclusive basis to Immunodiagnostic Systems (IDS) in 1996. The antibody was incorporated into a kit for the diagnosis of bone and calcium disorders. |
| |
| Renovo Group plc |
Professor Mark Ferguson and Dr Sharon O' Kane |
Renovo was founded by Professor Mark Ferguson and Dr Sharon O' Kane and was established in 2000. The company develops drugs to prevent and reduce scarring at multiple sites on the body and to accelerate healing. Renovo was admitted to the main market of the London Stock Exchange in April 2006 and raised £57.5M from new investors and £10M from existing Venture Capitalists. |
| |
| |
MHS
| |
| Project name |
Academic |
Description |
| |
| Myconostica Ltd |
Prof. David Denning |
Myconostica was founded by Professor David Denning from the School of Medicine and was establised in 2008. The company develops and supplies molecular diagnostic products to aid speedy, accurate diagnosis of life-threatening fungal infections in humans. Myconostica received funding of £60,000 from UMIP's Proof of Principle fund and in 2008 completed the third close of a £5.4M investment round with £1M from The UMIP Premier Fund. The investment will support the launch of the company's first two products. |
| |
| Pathogenic Tau Mutation |
Dr Stuart Pickering-Brown |
In 1997 Dr Stuart Pickering-Brown from The School of Medicine was conducting research into frontotemporal dementia. Key collaboration with the Mayo Clinic in 1998 finally proved that Tau disfunction could lead to dementia. In 2007, the jointly-owned Pathogenic Tau Mutation was licensed to Merck. |
| |
| |
 |
